Sector News

Shire weighs Takeda's cash-sweetened $61.5B offer

April 24, 2018
Life sciences

The third time wasn’t the charm for Takeda in its attempts to swallow Shire—but the fourth time might be.

On Friday, the Dublin drugmaker said it had received a new offer from Japan’s largest pharma, comprising £26 per share in new Takeda shares and and £21 per share in cash—good for £47 per share total, or about £44 billion ($61.6 billion).

And unlike Takeda’s first three bids of £46.50, £45.50 and £44.00 per share, which Shire rejected, the company is actually considering this one.

“The board of Shire is considering its position with respect to the fourth proposal and will issue a further announcement in due course,” it said in a statement.

The news comes just one day after word that Shire had already shot down the trio of Takeda bids. Thursday also saw traditionally M&A-happy Allergan reveal that it had muscled its way into a spot at the dealmaking table, only to turn around and walk away a few hours later, to the market’s great relief.

Still, the flip-flop may have struck a little fear into Takeda, which doesn’t have a whole lot of room to keep raising its offer without going into serious debt. Several U.S. drugmakers, on the other hand, are rolling in potential dealmaking funds thanks to tax reform, and industry watchers have floated a few of them—think Pfizer, Amgen and AbbVie, which has already struck one deal for Shire—as potential suitors.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).